Thromb Haemost 2000; 84(03): 484-491
DOI: 10.1055/s-0037-1614049
Commentary
Schattauer GmbH

Desensitization of the Platelet Aggregation Response to ADP: Differential Down-regulation of the P2Y1 and P2cyc Receptors

Anthony Baurand
1   From INSERM U.311, Etablissement Français du Sang-Alsace, Strasbourg, France
,
Anita Eckly
1   From INSERM U.311, Etablissement Français du Sang-Alsace, Strasbourg, France
,
Nadège Bari
1   From INSERM U.311, Etablissement Français du Sang-Alsace, Strasbourg, France
,
Catherine Léon
1   From INSERM U.311, Etablissement Français du Sang-Alsace, Strasbourg, France
,
Béatrice Hechler
1   From INSERM U.311, Etablissement Français du Sang-Alsace, Strasbourg, France
,
Jean-Pierre Cazenave
1   From INSERM U.311, Etablissement Français du Sang-Alsace, Strasbourg, France
,
Christian Gachet
1   From INSERM U.311, Etablissement Français du Sang-Alsace, Strasbourg, France
› Author Affiliations
The authors would like to thank Juliette Mulvihill for reviewing the English of the manuscript.
Further Information

Publication History

Received 21 October 1999

Accepted after resubmission 03 April 2000

Publication Date:
14 December 2017 (online)

Summary

Platelets activated by ADP become refractory to restimulation, but the mechanism of this process is not well understood. A normal platelet response to ADP requires coactivation of the P2Y1 receptor responsible for shape change and the P2cyc receptor, responsible for completion and amplification of the response. The aim of the present study was to characterize the desensitization of platelets to ADP and to determine whether or not these two receptors are desensitized simultaneously through identical pathways when platelets become refractory to ADP. It was found that full inhibition of platelet aggregation in response to restimulation by ADP required the presence of ADP in the medium or use of a high concentration (1 mM) of its non-hydrolysable analogue ADP β S. Platelets incubated for 1 h at 37° C with 1 mM ADP β S and resuspended in Tyrode’s buffer containing apyrase displayed a stable refractory state characterized by the inability to aggregate or change shape in response to ADP. ADP β S treated platelets loaded with fura2/AM showed complete blockade of the calcium signal in response to ADP, whereas the capacity of ADP to inhibit PGE1 stimulated cAMP accumulation in these platelets was only diminished. Consequently, serotonin was able to promote ADP induced aggregation through activation of the Gq coupled 5HT2A receptor while adrenaline had no such effect. These results suggested that the refractory state of ADP β S treated platelets was entirely due to desensitization of the P2Y1 receptor, the P2cyc receptor remaining functional. Binding studies were performed to determine whether the P2Y1 and/or P2cyc binding sites were modified in refractory platelets. Using selective P2Y1 and P2cyc antagonists (A3P5P and AR-C66096 respectively), we could demonstrate that the decrease in [33P]2MeSADP binding sites on refractory platelets corresponded to disappearance of the P2Y1 sites with no change in the number of P2cyc sites, suggesting internalization of the P2Y1 receptor. This was confirmed by flow cytometric analysis of Jurkat cells expressing an epitope-tagged P2Y1 receptor, where ADP β S treatment resulted in complete loss of the receptor from the cell surface. We conclude that the P2Y1 and P2cyc receptors are differently regulated during platelet activation.

 
  • References

  • 1 Lohse MJ. Molecular mechanisms of membrane receptors desensitization. Biochim Biophys Acta 1993; 1179: 171-88.
  • 2 Bünemann M, Lee KB, Pals-Rylaarsdam R, Roseberry AG, Hosey MM. Desensitization of G-protein-coupled receptors in the cardiovascular system. Annu Rev Physiol 1999; 61: 169-92.
  • 3 O’Brien JR. Changes in platelet membranes possibly associated with platelet stickiness. Nature 1966; 212: 1057-8.
  • 4 Spaet TH, Lejnieks I. Studies on the mechanism whereby platelets are clumped by adenosine diphosphate. Thromb Diath Haemorrh 1966; 15: 36-51.
  • 5 Gaarder A, Jonsen J, Laland S, Hellem A, Owren PA. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961; 192: 531-2.
  • 6 Mills DC. ADP receptors on platelets. Thromb Haemost 1996; 76: 835-56.
  • 7 O’Brien JR, Etherington M, Jamieson S. Refractory state of platelet aggregation with major operations. Lancet 1971; 02 7727 741-3.
  • 8 Holme S, Holmsen H. ADP-induced refractory state of platelets in vitro (I – Methodological studies on aggregation in platelet rich plasma). Scand J Haematol 1975; 15: 96-103.
  • 9 Holme S, Sixma JJ, Wester J, Holmsen H. ADP-induced refractory state of platelets in vitro (II – Functional and ultra studies on gel filtered platelets). Scand J Haematol 1977; 18: 267-78.
  • 10 Ardlie NG, Perry DW, Packham MA, Mustard JF. Influence of apyrase on stability of suspensions of washed rabbit platelets. Proc Soc Exp Biol Med 1971; 136: 1021-3.
  • 11 Fijnheer R, Boomgaard MN, van den Eertwegh AJ, Homburg CH, Gouwerok CW, Veldman HA, Roos D, de Korte D. Stored platelets release nucleotides as inhibitors of platelet function. Thromb Haemost 1992; 68: 595-9.
  • 12 Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Alyonycheva TN, Safier LB, Hajjar KA, Posnett DN, Schoenborn MA, Schooley KA, Gayle RB, Maliszewski CR. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest 1997; 99: 1351-60.
  • 13 Robson SC, Kaczmarek E, Siegel JB, Candinas D, Koziak K, Millan M, Hancock WW, Bach FH. Loss of ATP diphosphohydrolase activity with endothelial cell activation. J Exp Med 1997; 185: 153-63.
  • 14 MacKenzie AB, Mahaut-Smith MP, Sage SO. Activation of receptoroperated cation channels via P2X1 not P2T purinoceptors in human platelets. J Biol Chem 1996; 271: 2879-81.
  • 15 Vial C, Hechler B, Léon C, Cazenave JP, Gachet C. Presence of P2X1 purinoceptors in human platelets and megakaryoblastic cell lines. Thromb Haemost 1997; 78: 1500-4.
  • 16 Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol 1999; 19: 2281-5.
  • 17 Léon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P, Dierich A, LeMeur M, Cazenave JP, Gachet C. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y1 receptor null mice. J Clin Invest 1999; 104: 1731-7.
  • 18 Takano S, Kimura J, Matsuoka I, Ono T. No requirement of P2X1 purinoceptors for platelet aggregation. Eur J Pharmacol 1999; 372: 305-9.
  • 19 Hechler B, Léon C, Vial C, Vigne P, Frelin C, Cazenave JP, Gachet C. The P2Y1 receptor is necessary for adenosine-5’-diphosphate-induced platelet aggregation. Blood 1998; 92: 152-9.
  • 20 Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation – II – The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 1998; 273: 2030-4.
  • 21 Jin J, Kunapuli SP. Coactivation of two different G-protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci USA 1998; 95: 8070-4.
  • 22 Hechler B, Eckly A, Ohlmann P, Cazenave JP, Gachet C. The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel. Br J Haematol 1998; 103: 858-66.
  • 23 Geiger J, Brich J, Hönig-Liedl P, Eigenthaler M, Schanzenbacher P, Herbert JM, Walter U. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signalling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 1999; 19: 2007-11.
  • 24 Humphries RG, Tomlinson W, Ingall AH, Cage PA, Leff P. FPL66096: a novel, highly potent and selective antagonist at human platelet P2Tpurinoreceptors. Br J Pharmacol 1994; 113: 1057-63.
  • 25 Fagura MS, Dainty IA, McKay GD, Kirk IP, Humphries RG, Robertson MJ, Dougall IG, Leff P. P2Y1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors. Br J Pharmacol 1998; 124: 157-64.
  • 26 Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP. Molecular basis for ADP-induced platelet activation -IEvidence for three distinct ADP receptors on human platelets. J Biol Chem 1998; 273: 2024-9.
  • 27 Trumel C, Payrastre B, Plantavid M, Hechler B, Viala C, Presek P, Martinson EA, Cazenave JP, Chap H, Gachet C. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1 activating peptide through the late activation of phosphoinositide 3-kinase. Blood 1999; 94: 4156-65.
  • 28 Ohlmann P, Laugwitz KL, Nürnberg B, Spicher K, Schultz G, Cazenave JP, Gachet C. The human platelet ADP receptor activates Gi2 proteins. Biochem J 1995; 312: 775-9.
  • 29 Fredholm BB, Abbracchio MP, Burnstock G, Dubyak GR, Harden TK, Jacobson KA, Schwabe U, Williams M. Towards a revised nomenclature for P1 and P2 receptors. Trends Pharmacol Sci 1997; 18: 79-82.
  • 30 Cazenave JP, Hemmendinger S, Beretz A, Sutter-Bay A, Launay J. L’agrégation plaquettaire: outil d’investigation clinique et d’étude pharmacologique – Méthodologie. Ann Biol Clin 1983; 41: 167-79.
  • 31 Gachet C, Cattaneo M, Ohlmann P, Hechler B, Lecchi A, Chevalier J, Cassel D, Mannucci PM, Cazenave JP. Purinoreceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol 1995; 91: 434-44.
  • 32 Munson PJ, Rodbard D. LIGAND: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 1980; 107: 220-39.
  • 33 Palmer RK, Boyer JL, Schachter JB, Nicholas RA, Harden TK. Agonist action of adenosine triphosphates at the human P2Y1 receptor. Mol Pharmacol 1998; 54: 1118-23.
  • 34 Savi P, Beauverger P, Labouret C, Delfaud M, Salel V, Kaghad M, Herbert JM. Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS Lett 1998; 422: 291-5.
  • 35 Léon C, Vial C, Gachet C, Ohlmann P, Hechler B, Cazenave JP, Lecchi A, Cattaneo M. The P2Y1 receptor is normal in a patient presenting a severe deficiency of ADP-induced platelet aggregation. Thromb Haemost 1999; 81: 775-81.
  • 36 Zimmermann H. Nucleotides and cd39: Principal modulatory players in hemostasis and thrombosis. Nature Med 1999; 05: 987-8.
  • 37 Enjyoji K, Sévigny J, Lin Y, Frenette PS, Christie PD, Schulte II JAm Esch, Imai M, Edelberg JM, Rayburn H, Lech M, Beeler Dl, Csizmadia E, Wagner DD, Robson SC, Rosenberg RD. Targeted disruption of cd39 /ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nature Med 1999; 05: 1010-7.
  • 38 Lalau-Keraly C, Kinlough-Rathbone RL, Mustard JF. Epinephrine-induced aggregation of rabbit platelets refractory to ADP. Thromb Haemost 1985; 53: 366-71.
  • 39 Oury C, Lenaerts T, Peerlinck K, Vermylen J, Hoylaerts MF. Congenital deficiency of the phospholipase C coupled platelet P2Y1 receptor leads to a mild bleeding disorder. Thromb Haemost. 1999 (suppl) 20. (abstract)